Alligator Bioscience has announced the initiation a sponsored research collaboration to study biomarker data from Alligator’s OPTIMIZE-1 study with the University of Pennsylvania’s (UPENN) Pancreatic Cancer Research Center.
Gregory Beatty, assistant professor of Medicine in the Division of Hematology/Oncology, UPENN, will serve as the faculty investigator for the sponsored Research agreements. Data analysis by Dr. Beatty and his team will be conducted at the Beatty Laboratory at UPENN.
The priority of Dr. Beatty’s study will be to apply their analytical capabilities on data collected on patients receiving mFOLFIRINOX in combination with mitazalimab, Alligator’s agonistic CD40 antibody. The UPENN study is a part of Alligator’s OPTIMIZE-1 clinical trial, an open-label, multi-center phase 1B/I I trial assessing the clinical efficacy of mitazalimab in combination with chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic cancer. Enrollment of OPTIMIZE-1 is planned for up to 67 patients.
“The addition of the UPENN study, conducted by a researcher of Dr. Beatty’s caliber, to Alligator’s on-going OPTIMIZE-1 trail is very exciting. The resulting data will provide additional and valuable insight into the clinical development opportunities for mitazalimab in a patient population with high unmet medical needs,” says Alligator’s CEO, Søren Bregenholt. “We are also thrilled to welcome Dr. Beatty as a scientific advisor to Alligator.”
Photo of Søren Bregenholt, CEO, Alligator Bioscience